Skip to main content
Poly-Refractory Rheumatoid Arthritis

Refractory of difficult to treat (D2T-RA) rheumatoid arthritis (RA) comprises a mi

Dr. John Cush RheumNow

2 years 6 months ago
Poly-Refractory Rheumatoid Arthritis Refractory of difficult to treat (D2T-RA) rheumatoid arthritis (RA) comprises a minority of patients that can be categorized by clinical and imaging parameters to formulate a better therapeutic approach. https://t.co/IKAojQFdaw https://t.co/paBwWw2nmh
Full read overview of SJOGRENS SYNDROME, which can be Primary SS or Secondary (15% in SLE, 20% RA, & 30% systemic s

Dr. John Cush RheumNow

2 years 6 months ago
Full read overview of SJOGRENS SYNDROME, which can be Primary SS or Secondary (15% in SLE, 20% RA, & 30% systemic sclerosis). SS Organ involvement: - CNS 2-17% - Renal <=10% - ILD 10-20% -MSK 45-56% https://t.co/RElOFfP2xr https://t.co/aJI041VCuE
Favoralbe Survival w/ MDA-5 Ab+. 154 pts w/ MDA5+DM; 40 died (26%) Rx induction (mostly resp. failure). 114 survived, w/

Dr. John Cush RheumNow

2 years 6 months ago

Favorable Survival w/ MDA-5 Ab+. 154 pts w/ MDA5+DM; 40 died (26%) Rx induction (mostly resp. failure). 114 survived, w/ 5-yr survival of 97% & relapse-free survival 77%. Survival improved w/ JAKi use (P=.03). 8% achieved complete drug-free remission. https://t.co/QkqM9IztEG https://t.co/yBCH85CpUN

Systematic review of 44 studies looking at treatment of Stills Dz (AOSD), showing that tocilizumab, anakinra & cana

Dr. John Cush RheumNow

2 years 6 months ago
Systematic review of 44 studies looking at treatment of Stills Dz (AOSD), showing that tocilizumab, anakinra & canakinumab therapy are effective in AOSD. Complete remission: - TCZ 80% (57% Steroid D/C) - ANAK 73% (47% GC DC) - CAN 77% (34% GC DC) https://t.co/bFil81GGlJ https://t.co/F5NJ6m1gVF
It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. In an ideal world this would involve a combined clinic with our local friendly dermatologist. For many of us, however, this is not practical for many reasons. The excellent Saturday morning session on choosing systemic therapies in psoriatic disease at RheumNow Live 2024 from dermatologist extraordinaire Dr. April Armstrong was therefore
Full read, review of COLCHICINE, a, w/ narrow therapeutic index, & assoc. w/ overdose & fatalities. Discuss Int

Dr. John Cush RheumNow

2 years 6 months ago
Full read, review of COLCHICINE, a, w/ narrow therapeutic index, & assoc. w/ overdose & fatalities. Discuss Interactions, unauthorized access, overdoses, inappropriate dosing. No dose adjustments w/ Liver dz, but modest changes w/ severe CKD, dialysis https://t.co/53aOA4uqdY https://t.co/fuEwWsXMZG
JAMA Clinical Challenge - Recurrent Fever, Rash, and Shortness of Breath in a 69-Year-Old. Admited with fever, fatigue

Dr. John Cush RheumNow

2 years 6 months ago
JAMA Clinical Challenge - Recurrent Fever, Rash, and Shortness of Breath in a 69-Year-Old. Admited with fever, fatigue, rash, right periorbital swelling, SOB, Palpable purpural, Serositis previously - whats your diagnosis? https://t.co/j6aSGffpPv https://t.co/du6pEo74xp
Determinants of Gout Flares

Approximately 12 million US adults in the US have gout. Two recent literature reports high

Dr. John Cush RheumNow

2 years 6 months ago
Determinants of Gout Flares Approximately 12 million US adults in the US have gout. Two recent literature reports highlight contributors to gout flares. https://t.co/F2eiWXOTkF https://t.co/YFftaITmnQ
J&J announced the results of Phase 2 DAHLIAS study of nipocalimab in Sjögren’s; w/ a signif reduction in clinESS

Dr. John Cush RheumNow

2 years 6 months ago
J&J announced the results of Phase 2 DAHLIAS study of nipocalimab in Sjögren’s; w/ a signif reduction in clinESSDAI at week 24 vs placebo. Nipocalimab is an investigational anti-FcRn treatment being studied in RA, & myasthenia gravis https://t.co/mroLPx0BnH https://t.co/7IqlY1K6di
Acute CPPD at significantly higher risk of fractures. 1148 acute CPPD pts matched to 3730 comparators(mean 73 yrs old)

Dr. John Cush RheumNow

2 years 6 months ago
Acute CPPD at significantly higher risk of fractures. 1148 acute CPPD pts matched to 3730 comparators(mean 73 yrs old); Steroids and OP more in CPPD pts. Fx risk was twice as high in the acute CPPD pts (HR 1.8;1.3, 2.3). Fx risk highest forwrist (HR, 3.6) https://t.co/RkuzGKzoPv https://t.co/IHZBIfEmms
Racial and Ethnic Determinants of Psoriatic Arthritis

A study from a large metropolitan registry of psoriatic arthriti

Dr. John Cush RheumNow

2 years 6 months ago
Racial and Ethnic Determinants of Psoriatic Arthritis A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity. https://t.co/uJD5DWZEwM https://t.co/5dg0ubQzvL
Danish registries study shows maternal Autoimmune Dzs (all) were assoc w/ incr risk of childhood cancers (OR=1.25, 95% C

Dr. John Cush RheumNow

2 years 6 months ago
Danish registries study shows maternal Autoimmune Dzs (all) were assoc w/ incr risk of childhood cancers (OR=1.25, 95% CI 1.06, 1.47), acute lymphoblastic leukemia (OR =1.52), Burkitt lymphoma (OR=2.6) & CNS tumors (OR=1.45); same seen for RA mothers https://t.co/HQO972ch9R https://t.co/dDEJUo8unq
SeXXist Reason for More Women with Autoimmune Disease

Somewhere between 24 and 50 million Americans have an autoimmune

Dr. John Cush RheumNow

2 years 6 months ago
SeXXist Reason for More Women with Autoimmune Disease Somewhere between 24 and 50 million Americans have an autoimmune disease, a condition in which the immune system attacks our own tissues. As many as 4 out of 5 of those people are women. https://t.co/OCHNNhAgF2 https://t.co/7tfttSherh
Full read overview of SJOGRENS SYNDROME, which can be Primary SS or Secondary (15% in SLE, 20% RA, & 30% systemic s

Dr. John Cush RheumNow

2 years 6 months ago
Full read overview of SJOGRENS SYNDROME, which can be Primary SS or Secondary (15% in SLE, 20% RA, & 30% systemic sclerosis). SS Organ involvement: - CNS 2-17% - Renal <=10% - ILD 10-20% -MSK 45-56% https://t.co/0sfQdZAeGg https://t.co/3lSoGan1h9
Full read, review of COLCHICINE, a, w/ narrow therapeutic index, & assoc. w/ overdose & fatalities. Discuss Int

Dr. John Cush RheumNow

2 years 6 months ago
Full read, review of COLCHICINE, a, w/ narrow therapeutic index, & assoc. w/ overdose & fatalities. Discuss Interactions, unauthorized access, overdoses, inappropriate dosing. No dose adjustments w/ Liver dz, but modest changes w/ severe CKD, dialysis https://t.co/fx7G3MYArN https://t.co/azSHyBfPoi
×